EUVIMEDEUVIMED entdecken
Fallbericht

Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)

Jessica Barrett, Ernest Muntengesa, Clare Warrell, Tommy Rampling, Jodie Owen, Dipti Patel, Sanjay Bhagani iD, Rachel Moores, Antonia Scobie

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae484 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Jessica Barrett und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection, North Bristol NHS Trust, Bristol, UK. Hauptthemen laut MEDLINE: Sofosbuvir, Yellow Fever, Antiviral Agents, Post-Exposure Prophylaxis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Yellow fever–associated viscerotropic disease (YEL-AVD) is a rare but serious complication arising from administration of live-attenuated yellow fever vaccine to individuals with risk factors such as thymectomy. At present there is no evidence-based treatment, and case fatality rates are high. Sofosbuvir, an NS5B nucleotide inhibitor, has activity against yellow fever virus in vitro and in vivo. Patient and methods Here we describe clinical and virological response to use of off-licence sofosbuvir as post-exposure prophylaxis for a patient inadvertently given yellow fever vaccine despite previous thymectomy.

Results

A 14-day course of oral sofosbuvir was administered in an outpatient setting with regular clinical and biochemical monitoring. The patient remained well without developing clinical features of YEL-AVD and did not experience adverse effects from the treatment.

Conclusions

This supports the use of sofosbuvir as post-exposure prophylaxis in patients at high risk of developing YEL-AVD. Ongoing trials of efficacy of sofosbuvir in yellow fever infection may result in stronger support for this approach in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SofosbuvirYellow FeverAntiviral AgentsPost-Exposure ProphylaxisHumansYellow Fever VaccineMaleYellow fever virusMiddle AgedFemaleTreatment OutcomeAdministration, Oral

Substanzen

SofosbuvirAntiviral AgentsYellow Fever Vaccine

Autor:innen und Institutionen

  • Department of Infection, North Bristol NHS Trust, Bristol, UK.
  • Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.
  • Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Salisbury, UK.
  • National Travel Health Network and Centre (NaTHNaC), UCLH NHS Foundation Trust, London, UK.

ORCID-Profile: Sanjay Bhagani

Zitieren

APA

Barrett, J., Muntengesa, E., Warrell, C., Rampling, T., Owen, J., Patel, D., Bhagani, S., Moores, R., & Scobie, A. (2025). Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae484

Vancouver

Barrett J, Muntengesa E, Warrell C, Rampling T, Owen J, Patel D, et al. Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD). Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae484

BibTeX
@article{Barrett2025,
  author = {Barrett, Jessica and Muntengesa, Ernest and Warrell, Clare and Rampling, Tommy and Owen, Jodie and Patel, Dipti and Bhagani, Sanjay and Moores, Rachel and Scobie, Antonia},
  title = {Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae484}
}
Kostenlos starten →